hrp0086p2-p384 | Gonads & DSD P2 | ESPE2016

The Efficacy and Safety of Gonadotropin-Releasing Hormone Analogue Treatment to Suppress Puberty in Gender Dysphoric Adolescents

Hannema Sabine , Schagen Sebastian

Background: Puberty suppression using gonadotropin releasing hormone analogues (GnRHa) is recommended by current guidelines. Although GnRHa have long been used to treat children with precocious puberty there are few data on the outcome of this treatment in gender dysphoric adolescents.Objective and hypotheses: We aimed to evaluate the efficacy and safety of triptorelin to suppress puberty in a cohort of gender dysphoric adolescents.<p class="abstext"...

hrp0086p1-p357 | Gonads &amp; DSD P1 | ESPE2016

Changes in Adrenal Steroids During Puberty Suppression and Cross Sex Hormone Treatment in Gender Dysphoric Adolescents

Schagen Sebastian , Lustenhouwer Paul , Hannema Sabine

Background: Current guidelines recommend that gender dysphoric adolescents be treated with puberty suppression using gonadotropin releasing hormone analogues (GnRHa) followed by cross sex hormones. However limited data are available on the safety and side effects of this treatment. In adults changes in adrenal steroids have been observed during cross sex hormone treatment.Objective and hypotheses: We aimed to investigate the effect of GnRHa and cross sex...

hrp0084p1-119 | Puberty | ESPE2015

Lipid Profiles in Gender Dysphoric Adolescents Treated with GnRH Agonists Alone and in Combination with Cross-Sex Hormones

Schagen Sebastian , Delemarre-van de Waal Henriette , Hannema Sabine

Background: In gender dysphoric adolescents GnRH agonists can be used to suppress pubertal development of the natal sex. Subsequently cross sex hormones can be given to induce pubertal development of the experienced gender. Only few data are available on the safety of this treatment. Lipid levels are known to increase during puberty and pubertal suppression may alter this increase. In gender dysphoric male-to female (MtF) adults oestrogens has been shown to result in a more fa...

hrp0084p2-263 | Diabetes | ESPE2015

Insulin Sensitivity in Adolescents with Gender Dysphoria During Puberty Suppressing Therapy with GnRH Agonists

Schagen Sebastian , Delemarre-van de Waal Henriette , Hannema Sabine

Background: In gender dysphoric adolescents GnRH agonists can be used to suppress pubertal development of the natal sex. The metabolic implications of the pubertal suppression have not yet been explored. Insulin sensitivity is known to be influenced by pubertal changes. During puberty a decrease in insulin sensitivity is normally observed.Objective and hypotheses: The effects of GnRH agonists on insulin sensitivity during 2 years of treatment in adolesce...

hrp0082fc14.1 | Puberty | ESPE2014

Brain Structure and Function in Gender Dysphoric Adolescents

Hannema Sabine , Schagen Sebastian , Hoekzema Elseline , Kreukels Baudewijntje , Veltman Dick , Cohen-Kettenis Peggy , Bakker Julie , Delemarre-van de Waal Henriette

Background: Gender dysphoria is characterised by an incongruency between the perceived gender identity and the biological sex. The cause of gender dysphoria is unclear and environmental as well as genetic factors may be important. It is well known that during sexual differentiation sex steroids control not only the differentiation of the internal and external genitalia but also the sexual differentiation of the brain. Structural as well as functional differences have been show...